Latest Insider Transactions at Elevance Health, Inc. (ELV)
This section provides a real-time view of insider transactions for Elevance Health, Inc. (ELV). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Elevance Health, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Elevance Health, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
May 25
2021
|
John E Gallina EVP & Chief Financial Officer |
SELL
Bona fide gift
|
Direct |
3,301
-6.08%
|
-
|
May 24
2021
|
John E Gallina EVP & Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
46,444
-11.36%
|
$18,345,380
$395.65 P/Share
|
May 24
2021
|
John E Gallina EVP & Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
46,444
+9.83%
|
$7,523,928
$162.05 P/Share
|
May 24
2021
|
Ramiro G Peru Director |
SELL
Open market or private sale
|
Direct |
1,308
-12.14%
|
$520,584
$398.02 P/Share
|
May 21
2021
|
Robert L Dixon Jr Director |
SELL
Open market or private sale
|
Direct |
590
-6.17%
|
$231,280
$392.87 P/Share
|
May 20
2021
|
Julie A Hill Director |
SELL
Open market or private sale
|
Direct |
1,308
-4.02%
|
$515,352
$394.0 P/Share
|
Mar 22
2021
|
Peter D Haytaian EVP & Pres Carelon & CarelonRx |
SELL
Open market or private sale
|
Direct |
59,500
-15.49%
|
$20,765,500
$349.35 P/Share
|
Mar 22
2021
|
Peter D Haytaian EVP & Pres Carelon & CarelonRx |
BUY
Exercise of conversion of derivative security
|
Direct |
38,093
+21.14%
|
$5,294,927
$139.36 P/Share
|
Mar 05
2021
|
Ronald W Penczek CAO & Controller |
SELL
Open market or private sale
|
Direct |
2,068
-39.73%
|
$688,644
$333.94 P/Share
|
Mar 04
2021
|
Ronald W Penczek CAO & Controller |
SELL
Open market or private sale
|
Direct |
67
-1.27%
|
$21,641
$323.56 P/Share
|
Mar 02
2021
|
Peter D Haytaian EVP & Pres Carelon & CarelonRx |
SELL
Payment of exercise price or tax liability
|
Direct |
492
-1.11%
|
$153,012
$311.66 P/Share
|
Mar 02
2021
|
Felicia F Norwood EVP & President,Gov Health Ben |
SELL
Payment of exercise price or tax liability
|
Direct |
296
-0.96%
|
$92,056
$311.66 P/Share
|
Mar 02
2021
|
Leah Stark EVP & CHRO |
SELL
Payment of exercise price or tax liability
|
Direct |
715
-5.26%
|
$222,365
$311.66 P/Share
|
Mar 02
2021
|
Prakash R Patel EVP & President, DBG |
SELL
Payment of exercise price or tax liability
|
Direct |
551
-2.59%
|
$171,361
$311.66 P/Share
|
Mar 02
2021
|
Gloria M Mccarthy EVP & Chief Administrative Off |
SELL
Payment of exercise price or tax liability
|
Direct |
536
-0.95%
|
$166,696
$311.66 P/Share
|
Mar 02
2021
|
Ronald W Penczek CAO & Controller |
SELL
Payment of exercise price or tax liability
|
Direct |
42
-0.79%
|
$13,062
$311.66 P/Share
|
Mar 02
2021
|
John E Gallina EVP & Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
483
-0.88%
|
$150,213
$311.66 P/Share
|
Mar 02
2021
|
Gail Boudreaux President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,644
-1.61%
|
$511,284
$311.66 P/Share
|
Mar 01
2021
|
Peter D Haytaian EVP & Pres Carelon & CarelonRx |
BUY
Grant, award, or other acquisition
|
Direct |
26,032
+23.01%
|
-
|
Mar 01
2021
|
Peter D Haytaian EVP & Pres Carelon & CarelonRx |
SELL
Payment of exercise price or tax liability
|
Direct |
14,231
-43.6%
|
$4,425,841
$311.48 P/Share
|
Mar 01
2021
|
Felicia F Norwood EVP & President,Gov Health Ben |
BUY
Grant, award, or other acquisition
|
Direct |
14,641
+20.3%
|
-
|
Mar 01
2021
|
Felicia F Norwood EVP & President,Gov Health Ben |
SELL
Payment of exercise price or tax liability
|
Direct |
220
-1.34%
|
$68,420
$311.48 P/Share
|
Mar 01
2021
|
Leah Stark EVP & CHRO |
BUY
Grant, award, or other acquisition
|
Direct |
1,806
+11.72%
|
-
|
Mar 01
2021
|
Leah Stark EVP & CHRO |
SELL
Payment of exercise price or tax liability
|
Direct |
158
-1.32%
|
$49,138
$311.48 P/Share
|
Mar 01
2021
|
Jeffrey D. Alter EVP, IngenioRx & Anthem Health |
BUY
Grant, award, or other acquisition
|
Direct |
2,649
+32.93%
|
-
|
Mar 01
2021
|
Prakash R Patel EVP & President, DBG |
BUY
Grant, award, or other acquisition
|
Direct |
9,866
+19.98%
|
-
|
Mar 01
2021
|
Prakash R Patel EVP & President, DBG |
SELL
Payment of exercise price or tax liability
|
Direct |
186
-1.6%
|
$57,846
$311.48 P/Share
|
Mar 01
2021
|
Gloria M Mccarthy EVP & Chief Administrative Off |
BUY
Grant, award, or other acquisition
|
Direct |
26,032
+18.56%
|
-
|
Mar 01
2021
|
Gloria M Mccarthy EVP & Chief Administrative Off |
SELL
Payment of exercise price or tax liability
|
Direct |
11,971
-28.44%
|
$3,722,981
$311.48 P/Share
|
Mar 01
2021
|
Ronald W Penczek CAO & Controller |
BUY
Grant, award, or other acquisition
|
Direct |
2,895
+21.57%
|
-
|
Mar 01
2021
|
Ronald W Penczek CAO & Controller |
SELL
Payment of exercise price or tax liability
|
Direct |
818
-25.27%
|
$254,398
$311.48 P/Share
|
Mar 01
2021
|
John E Gallina EVP & Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
26,232
+19.23%
|
-
|
Mar 01
2021
|
John E Gallina EVP & Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
10,633
-27.12%
|
$3,306,863
$311.48 P/Share
|
Mar 01
2021
|
Blair Williams Todt EVP, CLO & CAO |
BUY
Grant, award, or other acquisition
|
Direct |
2,007
+41.72%
|
-
|
Mar 01
2021
|
Gail Boudreaux President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
83,835
+34.38%
|
-
|
Mar 01
2021
|
Gail Boudreaux President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
35,564
-66.26%
|
$11,060,404
$311.48 P/Share
|
Feb 04
2021
|
Ryan M. Schneider Director |
BUY
Open market or private purchase
|
Direct |
1,700
+36.79%
|
$503,200
$296.03 P/Share
|
Dec 30
2020
|
Felicia F Norwood EVP & President,Gov Health Ben |
SELL
Payment of exercise price or tax liability
|
Direct |
1,753
-9.64%
|
$550,442
$314.05 P/Share
|
Dec 30
2020
|
Prakash R Patel EVP & President, DBG |
SELL
Payment of exercise price or tax liability
|
Direct |
465
-3.85%
|
$146,010
$314.05 P/Share
|
Dec 30
2020
|
Leah Stark EVP & CHRO |
SELL
Payment of exercise price or tax liability
|
Direct |
328
-2.67%
|
$102,992
$314.05 P/Share
|
Dec 15
2020
|
Peter D Haytaian EVP & Pres Carelon & CarelonRx |
SELL
Open market or private sale
|
Direct |
5,833
-5.24%
|
$1,819,896
$312.73 P/Share
|
Dec 15
2020
|
Peter D Haytaian EVP & Pres Carelon & CarelonRx |
BUY
Exercise of conversion of derivative security
|
Direct |
5,833
+13.16%
|
$851,618
$146.93 P/Share
|
Dec 08
2020
|
John E Gallina EVP & Chief Financial Officer |
SELL
Bona fide gift
|
Direct |
2,589
-6.19%
|
-
|
Dec 01
2020
|
Blair Williams Todt EVP, CLO & CAO |
BUY
Grant, award, or other acquisition
|
Direct |
797
+50.0%
|
-
|
Dec 01
2020
|
Gail Boudreaux President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
14,764
-21.6%
|
$4,621,132
$313.9 P/Share
|
Nov 16
2020
|
Peter D Haytaian EVP & Pres Carelon & CarelonRx |
SELL
Open market or private sale
|
Direct |
5,834
-2.32%
|
$1,942,722
$333.9 P/Share
|
Nov 16
2020
|
Peter D Haytaian EVP & Pres Carelon & CarelonRx |
BUY
Exercise of conversion of derivative security
|
Direct |
1,708
+2.2%
|
$210,084
$123.85 P/Share
|
Nov 09
2020
|
Ronald W Penczek CAO & Controller |
SELL
Open market or private sale
|
Direct |
1,199
-27.08%
|
$395,670
$330.75 P/Share
|
Nov 03
2020
|
Thomas C Zielinski EVP & General Counsel |
SELL
Open market or private sale
|
Direct |
9,175
-10.2%
|
$2,679,100
$292.35 P/Share
|
Nov 03
2020
|
Thomas C Zielinski EVP & General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
1,893
+8.73%
|
$439,176
$232.04 P/Share
|